Melms A - Search Results

1

Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex-class II molecules.

Malcherek G, Gnau V, Jung G, Rammensee HG, Melms A. Malcherek G, et al. Among authors: melms a. J Exp Med. 1995 Feb 1;181(2):527-36. doi: 10.1084/jem.181.2.527. J Exp Med. 1995. PMID: 7836909 Free PMC article.

2

Analysis of allele-specific contact sites of natural HLA-DR17 ligands.

Malcherek G, Gnau V, Stevanovic S, Rammensee HG, Jung G, Melms A. Malcherek G, et al. Among authors: melms a. J Immunol. 1994 Aug 1;153(3):1141-9. J Immunol. 1994. PMID: 8027545

3

Natural peptide ligand motifs of two HLA molecules associated with myasthenia gravis.

Malcherek G, Falk K, Rötzschke O, Rammensee HG, Stevanović S, Gnau V, Jung G, Melms A. Malcherek G, et al. Among authors: melms a. Int Immunol. 1993 Oct;5(10):1229-37. doi: 10.1093/intimm/5.10.1229. Int Immunol. 1993. PMID: 8268130

4

Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs.

van Ham SM, Grüneberg U, Malcherek G, Bröker I, Melms A, Trowsdale J. van Ham SM, et al. Among authors: melms a. J Exp Med. 1996 Nov 1;184(5):2019-24. doi: 10.1084/jem.184.5.2019. J Exp Med. 1996. PMID: 8920889 Free PMC article.

5

MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation.

Malcherek G, Wirblich C, Willcox N, Rammensee HG, Trowsdale J, Melms A. Malcherek G, et al. Among authors: melms a. Eur J Immunol. 1998 May;28(5):1524-33. doi: 10.1002/(SICI)1521-4141(199805)28:05<1524::AID-IMMU1524>3.0.CO;2-T. Eur J Immunol. 1998. PMID: 9603457 Free article.

6

New ligands for HLA DRB1*0301 by random selection of favourable amino acids ranked by competition studies with undecapeptide amide sublibraries.

Jung C, Kalbus M, Fleckenstein B, Melms A, Jung G, Wiesmüller KH. Jung C, et al. Among authors: melms a. J Immunol Methods. 1998 Oct 1;219(1-2):139-49. doi: 10.1016/s0022-1759(98)00139-2. J Immunol Methods. 1998. PMID: 9831395

7

An example of immunodominance: engagement of synonymous TCR by invariant CDR3 beta.

Wienhold W, Malcherek G, Jung C, Stevanovic S, Jung G, Schild H, Melms A. Wienhold W, et al. Among authors: melms a. Int Immunol. 2000 Jun;12(6):747-56. doi: 10.1093/intimm/12.6.747. Int Immunol. 2000. PMID: 10837402

8

Ligand motif of the autoimmune disease-associated mouse MHC class II molecule H2-A(s).

Kalbus M, Fleckenstein BT, Offenhäusser M, Blüggel M, Melms A, Meyer HE, Rammensee HG, Martin R, Jung G, Sommer N. Kalbus M, et al. Among authors: melms a. Eur J Immunol. 2001 Feb;31(2):551-62. doi: 10.1002/1521-4141(200102)31:2<551::aid-immu551>3.0.co;2-p. Eur J Immunol. 2001. PMID: 11180120 Free article.

9

T cells from normal and myasthenic individuals recognize the human acetylcholine receptor: heterogeneity of antigenic sites on the alpha-subunit.

Melms A, Malcherek G, Gern U, Wiethölter H, Müller CA, Schoepfer R, Lindstrom J. Melms A, et al. Ann Neurol. 1992 Mar;31(3):311-8. doi: 10.1002/ana.410310314. Ann Neurol. 1992. PMID: 1379027

10

Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy.

Neidert MC, Schoor O, Trautwein C, Trautwein N, Christ L, Melms A, Honegger J, Rammensee HG, Herold-Mende C, Dietrich PY, Stevanović S. Neidert MC, et al. Among authors: melms a. J Neurooncol. 2013 Feb;111(3):285-94. doi: 10.1007/s11060-012-1028-8. Epub 2012 Dec 23. J Neurooncol. 2013. PMID: 23263746

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

179 results

Search Page

Filters